Bayer speeds up spinoff of plastics unit; Parexel chops 850 jobs amid corporate reshuffling;

@FiercePharma: HIV vaccine research a 'major advance,' NIH official says. FierceVaccines story | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. Feature from FiercePharmaManufacturing | Follow @EricPFierce

> Bayer looks to be accelerating the spinoff of its plastics unit, planning to finish preparations for the deal by late August, sources familiar with the matter told Reuters. Story

> CRO Parexel is laying off 850 employees amid a corporate overhaul, eyeing savings of between $50 million and $60 million once the reshuffling is complete. More

> European regulators gave their thumbs-up to Daiichi Sankyo's once-daily bloodthinner Lixiana to treat and prevent strokes in adult patients. Article

> The FDA is planning to hold a public panel meeting to hash out safety concerns for Bayer's contraceptive device, Essure. Story

> Novo Nordisk ($NVO) revealed data from two studies showing the emotional and physical toll hemophilia takes on patients and caregivers of people with the disorder. More

> The FDA issued a warning against Noven Therapeutics' Daytrana patch for ADHD, saying the drug may cause permanent loss of skin color, or chemical leukoderma. Statement

Medical Device News

@FierceMedDev: Google and the Broad Institute join forces for genomic data sharing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Chris Viehbacher explains: "If I had $2 billion to invest…" More from FierceBiotech | Follow @VarunSaxena2

@EmilyWFierce: Enthusiasm could be outpacing the evidence when it comes to genetic testing, experts say. More from the NYT | Follow @EmilyWFierce

> Zimmer Biomet is born after knee implant divestiture to S&N. More

> FDA panel slated to weigh Bayer Essure safety after more than 5,000 complaints. Story

> Covidien settles the score in more than 11,000 vaginal mesh cases. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Little NeuroRx boasts big about a new ketamine combo for bipolar depression. Article | Follow @FierceBiotech

@JohnCFierce: Isn't it strange that biotech is booming and R&D jobs have never been so uncertain? | Follow @JohnCFierce

> Catabasis pulls off a $60M IPO as biotech's Wall Street window stays open. Article

> London's mayor suggests quick $15B fix for financially ailing biotech sector. Story

> Bristol-Myers rips up its R&D group, adding, eliminating and moving hundreds. Report

Vaccines News

> Vical posts herpes vaccine PhI/II failure, gutting shares. News

> MERS getting more attention as vaccine candidate enters PhI. More

> ACIP gives Glaxo, Pfizer a lukewarm decision for new meningitis B vaccines. Story

> NIH grants Northeastern prof $1.4M to address 'bottleneck' in vaccine development. Article

> Pfizer to acquire GlaxoSmithKline meningitis vaccines for $130M. Report

CRO News

> PRA debuts a sweeping clinical trial operating system. More

> Novasep bets $11M on armed antibody R&D. Item

> Huntingdon and Harlan move forward under a new monicker. Article

> Icon rolls out some new patient-consent tech with a focus on education. Story

> Parexel cutting 850 jobs as it dims its revenue outlook. Report

Pharma Asia News

> S. Korea sees extra $9B in spending to handle MERS outbreak. Report

> Australia's Benitec heading for Nasdaq IPO. More

> Ascletis plans China, Taiwan PhIII trials on chronic hep C therapies. Story

> CRO M&A ticks up in India, fueling hopes of turnaround. Article

> South Korea biopharma IPOs highlight demand. Item

Pharma Manufacturing News

> Novasep building ADC manufacturing plant at Le Mans site. News

> Pharmacies want more time to comply with track-and-trace rules. Item

> TxCell halts drug production, a decision made with French regulator. Report

> FDA slaps U.S. drugmaker over drug testing issues. Story

> Hospira finally up and running at its cost-cutting India plant. Article

And Finally… Pfizer's ($PFE) arthritis drug Xeljanz restored skin color in a patient with the disfiguring skin condition vitiligo, according to dermatologists at Yale School of Medicine. Story

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.